Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.…
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics (NASDAQ: UNCY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 3.350 USD on 20 November 2026, down 25.2% over 52 weeks. Its 52-week range is 3.330 USD to 8.740 USD, and it trades at the bottom of that range.
Its market capitalisation is 97.77M USD.
Unicycive Therapeutics reports return on equity of -87.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 58.45M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.